A Randomized Phase II Trial of Consolidation Therapy Following CD19 CAR T-Cell Treatment for Relapsed/Refractory Diffuse Large B-Cell Lymphoma or Grade IIIB Follicular Lymphoma

Protocol No
SWOG-S2114
Phase
II
Summary

To find out if this approach is better or worse than the usual approach for DLBCL patients receiving CAR T-cell therapy. The usual approach for Relapsed/Refractory DLBCL patients is follow-up visits with no further therapy.

Description
To find out if this approach is better or worse than the usual approach for DLBCL patients receiving CAR T-cell therapy. The usual approach for Relapsed/Refractory DLBCL patients is follow-up visits with no further therapy.
Participating Institutions
Froedtert Hospital
Moorland Reserve Health Center
Status
OPEN TO ACCRUAL